# Safety and Efficacy of rAAV.hCNGA3 Gene Therapy in Patients With CNGA3-linked Achromatopsia

> **NCT02610582** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **STZ eyetrial** · enrollment: 13 (actual)

## Conditions studied

- Achromatopsia

## Interventions

- **DRUG:** rAAV.hCNGA3

## Key facts

- **NCT ID:** NCT02610582
- **Lead sponsor:** STZ eyetrial
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-11
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2024-04-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02610582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02610582, "Safety and Efficacy of rAAV.hCNGA3 Gene Therapy in Patients With CNGA3-linked Achromatopsia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02610582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*